Trials / Completed
CompletedNCT01774344
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 573 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to evaluate efficacy and safety of regorafenib in patients with advanced liver cancer who had progressed after sorafenib treatment. Patients were treated with regorafenib or placebo using a 2:1 randomization scheme.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib (Stivarga, BAY73-4506) | Regorafenib, 40 mg tablets |
| DRUG | Placebo | Placebo tablets matching in appearance |
Timeline
- Start date
- 2013-05-14
- Primary completion
- 2016-02-29
- Completion
- 2019-07-05
- First posted
- 2013-01-24
- Last updated
- 2020-08-20
- Results posted
- 2017-06-05
Locations
147 sites across 21 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, China, Czechia, France, Germany, Hungary, Italy, Japan, Netherlands, Russia, Singapore, South Korea, Spain, Switzerland, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01774344. Inclusion in this directory is not an endorsement.